Managing Complex Biomarker Data Archives - Page 5 of 5

May 20, 2020 — With new information around SARS-CoV-2 and COVID-19 surfacing on an almost daily basis, we are consistently reminded of the complexity and relatively unknown mechanisms behind why this disease presents with such a varying degree of severity. The impacts of COVID-19 infection on pediatric patients have been of particular concern in recent weeks given the apparent links of a severe Kawasaki-like disease, Pediatric Multisystem Inflammatory Syndrome (PMIS), coinciding with the pandemic. Incidence has been reported in the US and worldwide, with ~100 reports and three deaths in New York and the description of a broader outbreak in Italy outlined here.

May 18, 2020 — As the research community is generating data from novel research and looking to leverage prior research (e.g., MERS, SARS), there is significant opportunity to integrate these diverse data sources to create an even more valuable data asset for scientific insight generation. This opportunity requires addressing very real data wrangling challenges.

May 6, 2020 — Following Scott Marshall’s announcement last week about the QuartzBio team’s COVID-19-Related Data Aggregation Initiative, we wanted to share additional context behind the scope of our efforts. Our initial focus is creating a valuable and thoughtfully constructed data ecosystem, which will result in the ability to draw meaningful context. This is nucleated with published data from critical SARS-CoV-2 profiling experiments, that compare infection of cell line and animal models with novel coronavirus to other viruses like SARS-CoV, MERS-CoV and H1N1.

April 28, 2020 — COVID-19 is at the forefront of many research and development agendas. How can the integration of publicly available data help accelerate these efforts? The QuartzBio team is building and making available a unified SARS-CoV-2 / COVID-19 data ecosystem to support our own work and that of the broader research community. In the midst of the global pandemic, research and development teams face unprecedented operational hurdles affecting data generation.

March 10, 2020 — In the years to come, public data will play an increasingly important role in drug discovery and development.

data-driven-clinical-planning-white-paper-quartzbio-thumbnail

In this brief, learn how biotechs are strategically using publicly available data to:

Accelerate their path to the clinic by circumventing time-consuming, expensive data generation
Increase the likelihood of success by mitigating the reproducibility risks inherent in preclinical models
Quickly incorporate data-driven evidence to guide critical decisions related to indication matching, patient stratification, and MOA investigation
Build data assets that support their eventual regulatory filings

Download Brief

February 4, 2019 — Pharmaceutical and healthcare organizations have zettabytes of data at their disposal, literally. They have spent the last decade accumulating information from electronic health records, insurance claims, lab results and more. Whatever frustrations one might have with the industry at large, it can’t reasonably be suggested that companies were caught unaware by the data and analytics revolution. If anything, they have veered in the direction of over-collection and analysis.

January 15, 2020 — With public data set to play an increasingly important role in drug discovery and development, an integrated, data-driven approach to clinical planning can optimize the probability of success. The increasing availability of public data sets, such as The Cancer Genome Atlas (TCGA) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), offers a transformational opportunity for insight-driven planning at all phases of the drug development life cycle. The size and scope of these public data sets are often considerable, compiling billions of data points across multiple modalities and representing data that would have previously required many years and millions of dollars to generate.

November 13, 2019 — Quizartinib, a once-daily, oral, highly potent and selective FLT3 inhibitor, demonstrated a significant improvement in survival vs SC in FLT3-ITD-positive R/R AML in the global, randomized, phase 3 QuANTUM-R study (Cortes et al. Lancet Oncol, 2019; NCT02039726). Patients with R/R FLT3-ITD-positive AML were randomized 2:1 to receive single agent quizartinib or investigator’s choice of pre-selected SC.

View the poster

November 8, 2019 — This article explores biomarker data trends and challenges, and shares how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can reduce time and cost.

March 4, 2019 — Since the turn of the century, the use of biomarkers in drug discovery and development has exploded at an unprecedented rate. Recent scientific and technologic breakthroughs allow biomarkers to be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process—at a fraction of the cost and with turnaround times unimaginable less than a decade ago. Chad Clark et al., of Precision for Medicine, identify how these advances are driving a paradigm shift in drug discovery and development.